<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aggressive therapeutic maneuvers to reduce the risk for <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> are routine in the management of children receiving therapy for advanced stage Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and B cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The case histories of 40 children entered into a prospective treatment protocol for high-risk disease revealed that ten of 40 patients (25%) had <z:hpo ids='HP_0001919'>acute renal failure</z:hpo>, two at the time of hospital admission and eight in whom <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> developed 12 to 132 hours following initiation of cytotoxic chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Admission values for serum lactic dehydrogenase and serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> were not statistically different between patients with and without subsequent <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Urine output in the 12 hours prior to <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> therapy was 2.9 +/- 0.8 mL/kg/h in the eight children in whom <z:hpo ids='HP_0000083'>renal failure</z:hpo> developed and 5.3 +/- 0.4 mL/kg/h in the patients who did not (P less than .01) </plain></SENT>
<SENT sid="4" pm="."><plain>The urinary flow rate in the 24 hours following initiation of chemotherapy was significantly lower in children in whom <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> developed (1.0 +/- 0.2 mL/kg/h, mean +/- SE) compared with those who did not (3.7 +/- 0.3 mL/kg/h, P less than .001) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000083'>Renal failure</z:hpo> could not be attributed to <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> or <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> in the majority of patients with <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>One to four hemodialysis treatments (2.5 +/- 0.3) were required for the ten patients </plain></SENT>
<SENT sid="7" pm="."><plain>Serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> concentrations returned to <z:mpath ids='MPATH_458'>normal</z:mpath> in the nine survivors </plain></SENT>
<SENT sid="8" pm="."><plain>Response to initial <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> therapy was not affected by the presence of <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000083'>Renal failure</z:hpo> continues to be a major clinical problem in children with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and B cell lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>